Ensign Peak Advisors, Inc Avidity Biosciences, Inc. Transaction History
Ensign Peak Advisors, Inc
- $58.8 Billion
- Q3 2025
A detailed history of Ensign Peak Advisors, Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 580,857 shares of RNA stock, worth $41.1 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
580,857
Previous 329,978
76.03%
Holding current value
$41.1 Million
Previous $9.74 Million
159.83%
% of portfolio
0.04%
Previous 0.02%
Shares
6 transactions
Others Institutions Holding RNA
# of Institutions
312Shares Held
139MCall Options Held
1.24MPut Options Held
531K-
Janus Henderson Group PLC London, X014.5MShares$1.03 Billion0.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$936 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY11.4MShares$805 Million6.62% of portfolio
-
Wellington Management Group LLP Boston, MA10.1MShares$713 Million0.08% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.79MShares$693 Million0.05% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $3.69B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...